Parkinson's Disease Risk and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process Last reviewed: 2026-05-29
This page contains general information only. For personal health decisions, consult a qualified clinician.
Parkinson's Disease Risk reflects the cumulative effect of common genetic variants identified across more than a decade of genome-wide association research. Variants near ACMSD — a gene in the kynurenine pathway of tryptophan metabolism — are among the most studied loci in this neurological trait category, alongside ADD1 and ANO5. Below: the genetics, what robust replicated research shows, and practical steps for people with elevated-risk results.
What is Parkinson's Disease Risk?
Parkinson's disease is a progressive neurological condition characterized by the gradual loss of dopaminergic neurons in a midbrain region called the substantia nigra. The cardinal motor features — resting tremor, slowness of movement (bradykinesia), muscular rigidity, and postural instability — emerge as dopamine signaling becomes insufficient for smooth motor control. The pathological hallmark is the accumulation of Lewy bodies, which are intracellular aggregates of a misfolded protein called alpha-synuclein.
Parkinson's disease affects roughly 1–2 people per 1,000 in the general population worldwide, with prevalence rising sharply with age; estimates reach 1–2% of those over 60. It is the second most common neurodegenerative condition globally. The vast majority of cases are classified as idiopathic — meaning no single cause has been identified — though both genetic predisposition and environmental exposures are well-established contributors.
The ExomeDNA Parkinson's Disease Risk trait reflects common variant associations established through population-scale genetic studies. This is a polygenic signal: many variants, each of modest individual effect, combine to shift risk across the population distribution. Having a higher-than-average genetic score does not mean a person will develop the condition; conversely, a lower score does not rule it out. Environmental exposures, lifestyle patterns, and rare highly penetrant variants (such as those in LRRK2 or GBA, not covered by this page's GWAS panel) each contribute separately to individual risk.
The genetics behind Parkinson's Disease Risk
The common-variant genetic architecture of Parkinson's disease has been mapped through a series of large genome-wide association studies conducted from 2005 onward. The loci described on this page come from that foundational era of Parkinson's GWAS research — ten independent studies establishing replicated associations across multiple populations.
ACMSD — the kynurenine pathway connection
Among the most mechanistically compelling genes linked to Parkinson's disease risk on this page is ACMSD, which encodes the enzyme 2-aminomuconate semialdehyde decarboxylase. This enzyme operates within the kynurenine pathway — the dominant route by which the body catabolizes the amino acid tryptophan. In the kynurenine pathway, tryptophan is converted through a series of intermediates, one of which is 2-aminomuconate semialdehyde. ACMSD diverts this intermediate away from quinolinate, a potent neuronal excitotoxin.
Quinolinate is an endogenous agonist of NMDA glutamate receptors. When ACMSD activity is reduced — as may occur with certain common variants — less of the intermediate is diverted, and quinolinate levels in the central nervous system can rise. Elevated quinolinate drives excessive NMDA receptor activation, which floods neurons with calcium and triggers excitotoxic cell death. Dopaminergic neurons in the substantia nigra are thought to be particularly vulnerable to this mechanism, in part because of their intrinsic high-calcium pacemaking activity. The ACMSD story therefore connects tryptophan metabolism, NAD biosynthesis, and neuronal vulnerability in a single pathway.
ADD1 — cytoskeletal dynamics in dopaminergic neurons
ADD1 encodes alpha-adducin, a member of the adducin family of cytoskeletal proteins. Adducins form heterodimers and localize to the spectrin-actin network underlying the cell membrane. In neurons, ADD1 is involved in regulating ion transport, membrane dynamics, and presynaptic vesicle cycling. Variants near ADD1 have been identified in early Parkinson's GWAS cohorts, and the gene's role in neuronal membrane remodeling makes it a biologically plausible candidate. Disruptions in the cytoskeletal scaffolding that maintains presynaptic terminals in dopaminergic neurons could affect neurotransmitter release efficiency and synaptic maintenance.
ANO5 — calcium-activated chloride channel signaling
ANO5 encodes anoctamin 5, a calcium-activated chloride channel. Calcium dysregulation is a recurring theme in dopaminergic neuron vulnerability: these neurons rely on sustained L-type calcium channel-driven pacemaking, and perturbations in calcium handling increase cellular stress. ANO5 has been identified in genetic analyses of Parkinson's risk loci, and its role in calcium-gated ion transport provides a plausible link to the cellular environment in which dopaminergic neurons must function.
ADAMTS20 and extracellular matrix remodeling
ADAMTS20 is a zinc-dependent metalloprotease involved in extracellular matrix remodeling. While its role in neurodegeneration is less directly characterized than ACMSD or ADD1, the ECM environment of the substantia nigra is increasingly recognized as relevant to neuroinflammation and the spread of alpha-synuclein pathology. Genetic variation at this locus may modulate the tissue microenvironment in which dopaminergic neurons reside.
The polygenic architecture
No single gene on this page accounts for more than a small fraction of population-level Parkinson's risk. The genome broadly influences susceptibility, but environment, aging, and stochastic biological events are equally determinative of individual outcomes.
What the research says
Research base: Robust.
The GWAS-era Parkinson's literature represented by this page spans 2005 through 2011 and encompasses some of the most replicated findings in neurological genetics. Ten independent genome-wide association studies across multiple ethnicities and research consortia established the foundational architecture of common-variant Parkinson's risk.
Maraganore et al. (2005) conducted one of the first whole-genome association studies in Parkinson's disease.[1] Fung et al. (2006) extended this with genome-wide genotyping in cases and neurologically normal controls.[2] Simón-Sánchez et al. (2009) reported a large-scale GWAS identifying genetic risk at multiple novel loci.[3] Satake et al. (2009) identified common variants at four loci as genetic risk factors — including signals near SNCA and the MAPT region — providing replication across an East Asian population.[4]
Four independent loci confirmed in 2009 GWAS studies. Satake et al. (2009) identified common variants at four distinct genomic loci as genetic risk factors for Parkinson's disease across a large Japanese cohort — one of the first demonstrations of cross-ethnic replication for Parkinson's common-variant signals.[4]
Edwards et al. (2010) conducted a genome-wide association study confirming signals near SNCA and the MAPT region as common risk loci, adding a third independent replication data point for these associations.[5] Hamza et al. (2010) reported an unexpected finding: common genetic variation in the HLA region — the major histocompatibility complex — is associated with late-onset sporadic Parkinson's disease, pointing toward neuroinflammation and immune dysregulation as mechanisms.[6]
HLA variation linked to late-onset Parkinson's in 2010. Hamza et al. (2010) reported that common variants in the HLA region — best known for immune function — showed association with sporadic Parkinson's disease, suggesting that immune-mediated neuroinflammation may be a contributing pathway alongside classical dopaminergic degeneration.[6]
The UK Parkinson's Disease Consortium (2011) identified an additional locus through targeted dissection of Parkinson's genetics.[7] Saad et al. (2011) confirmed the BST1 locus and suggested a second signal on chromosome 12q24.[8] The International Parkinson Disease Genomics Consortium (2011) used imputation to refine genetic risk identification at previously identified loci.[9] Do et al. (2011) identified two novel loci via web-based GWAS and characterized substantial genetic overlap between Parkinson's disease and related traits.[10]
Collectively, this body of research established that the common-variant architecture of Parkinson's disease involves multiple biological pathways — neuronal metabolism (ACMSD, kynurenine pathway), cytoskeletal integrity (ADD1), immune function (HLA region), and protein aggregation (SNCA).
How Parkinson's Disease Risk affects you
Parkinson's disease typically manifests in the sixth decade of life or later, though early-onset forms (before age 50) exist and are more commonly associated with highly penetrant rare variants. The prodromal phase — the period before motor symptoms emerge — can last a decade or more and often includes non-motor features: loss of sense of smell (hyposmia), REM sleep behavior disorder (acting out dreams during sleep), constipation, and mood changes. These prodromal signs are not specific to Parkinson's, but for people who know they carry elevated polygenic risk, awareness of these features may prompt earlier clinical evaluation.
The motor syndrome of Parkinson's disease progresses over years and decades and varies substantially between individuals. Some people experience predominantly tremor-dominant disease with relatively slow progression; others develop prominent gait and balance difficulties earlier. Cognitive changes, including slowing of processing speed and, in later stages, dementia, affect a substantial proportion of those with the condition over time.
The common variants captured by this trait score shift population-level probability — they do not determine individual outcomes. For most people with a moderately elevated genetic score, the absolute lifetime risk remains below 5–10%. This result is an invitation to engage thoughtfully with modifiable factors and to stay informed about prodromal symptoms that would merit a clinical conversation.
Working with your Parkinson's Disease Risk result
The following lifestyle and environmental factors have shown associations with Parkinson's disease risk or progression in observational and prospective research. None of these constitute clinical guidance; they are patterns observed across populations and may not apply uniformly to individuals.
Regular aerobic exercise. Multiple cohort studies and meta-analyses have found that regular vigorous physical activity is associated with lower Parkinson's disease incidence. Exercise also supports dopaminergic function through BDNF upregulation and may have neuroprotective properties independent of its general cardiovascular benefits. A minimum of 150 minutes of moderate aerobic activity per week is the pattern associated with benefit in the epidemiological literature.[3,5]
Mediterranean or MIND dietary pattern. Observational studies have linked adherence to Mediterranean-style and MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) dietary patterns with lower risk of neurodegenerative outcomes. These diets emphasize vegetables, legumes, whole grains, fish, and olive oil, with limited red meat and processed food. The proposed mechanisms include reduced systemic inflammation and improved mitochondrial function in neurons.[3]
Coffee and caffeine consumption. Among the most consistently replicated inverse associations in Parkinson's epidemiology is caffeine intake. Multiple meta-analyses across Asian and Western populations have found that higher coffee consumption is associated with meaningfully lower Parkinson's incidence. The mechanism is not fully established, but adenosine A2A receptor antagonism — caffeine's primary pharmacological action — is a plausible pathway given the role of A2A receptors in modulating dopaminergic neurotransmission in the basal ganglia.[4,6]
Pesticide and organophosphate exposure avoidance. Agricultural cohort studies have consistently identified occupational or residential exposure to certain pesticides — particularly rotenone and paraquat — as associated with increased Parkinson's risk. For people with elevated genetic risk scores, minimizing exposure to these environmental neurotoxins (through food choices, occupational precautions, or residential decisions) is a prudent consideration.[5]
Head injury prevention. Traumatic brain injury, particularly repeated head trauma, has been consistently associated with increased Parkinson's risk in epidemiological studies. Protective equipment during sports and activities involving fall risk is relevant for people who carry elevated genetic risk.[7]
Sleep quality monitoring. REM sleep behavior disorder (RBD) — a condition in which people physically act out dreams during REM sleep — is a well-established prodromal marker for Parkinson's disease and related synucleinopathies. For those with elevated genetic risk, maintaining consistent sleep hygiene and consulting a clinician about persistent unusual sleep behaviors (thrashing, vocalizing, acting out dreams) may enable earlier detection of neurological changes worth investigating.[8,9]
Related traits and genes
Parkinson's Disease Risk shares genetic and biological architecture with several other traits in the ExomeDNA panel. Related results include Alzheimer's Disease Risk (neuroinflammatory and synaptic integrity pathways), Essential Tremor Risk (basal ganglia circuitry overlap), Restless Legs Syndrome (dopaminergic involvement), Caffeine Metabolism (relevant to the caffeine-Parkinson's inverse association), and Sleep Duration (REM sleep behavior disorder as a prodromal marker).
The ACMSD gene page provides a fuller mechanistic explanation of the kynurenine pathway and its relevance to neurodegeneration. See Methodology and Trust Center for data sources and editorial standards.
Frequently asked questions
Does a high Parkinson's Disease Risk score mean I will develop Parkinson's disease? No. A higher genetic score means your combination of common variants is associated with elevated population-level risk, but Parkinson's disease is a complex condition influenced by environment, aging, rare variants not captured by this score, and biological factors not yet fully characterized. The vast majority of people with elevated scores will not develop the condition within a normal lifespan. This result is best used as context for lifestyle awareness — not as a forecast.
What does the ACMSD gene have to do with Parkinson's disease? ACMSD encodes an enzyme that diverts the kynurenine pathway of tryptophan metabolism away from producing quinolinate, a neurotoxic compound. When ACMSD activity is reduced, quinolinate can accumulate and over-activate NMDA receptors in the brain — a process called excitotoxicity — which is harmful to dopaminergic neurons in the substantia nigra. This mechanistic link helps explain why variants near ACMSD have appeared across multiple Parkinson's GWAS studies.
How many studies support the genetic signals on this page? Ten independent genome-wide association studies published between 2005 and 2011 contribute to the evidence base for this trait. These span multiple cohorts across European and East Asian populations, representing one of the most replicated polygenic risk architectures in neurological genetics.
Can lifestyle changes meaningfully affect Parkinson's disease risk? Observational research supports several modifiable factors: regular aerobic exercise, Mediterranean-style diet, higher coffee intake, and pesticide avoidance have each shown inverse associations with Parkinson's incidence. These are population-level patterns; individual effects vary.
What are early signs that someone with elevated genetic risk should discuss with a clinician? Non-motor features that may precede motor Parkinson's symptoms include loss of smell (hyposmia), acting out dreams during sleep (REM sleep behavior disorder), constipation, and mood changes. For people aware of elevated genetic risk, discussing persistent occurrence of these features with a clinician is a reasonable step.
How does this trait differ from other Parkinson's risk scores? This page covers the foundational GWAS-era common-variant architecture of Parkinson's disease, focused on replicated loci near ACMSD, ADD1, and ANO5. Highly penetrant rare variants in LRRK2 or GBA are captured in separate clinical genetic testing frameworks and are not part of this polygenic score. For those with a family history of Parkinson's disease, a clinician or genetic counselor can discuss whether rare-variant testing is appropriate.
References
- Maraganore DM et al. (2005). High-resolution whole-genome association study of Parkinson disease. PMID: 16252231
- Fung HC et al. (2006). Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. PMID: 17052657
- Simón-Sánchez J et al. (2009). Genome-wide association study reveals genetic risk underlying Parkinson's disease. PMID: 19915575
- Satake W et al. (2009). Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. PMID: 19915576
- Edwards TL et al. (2010). Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. PMID: 20070850
- Hamza TH et al. (2010). Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. PMID: 20711177
- UK Parkinson's Disease Consortium (2011). Dissection of the genetics of Parkinson's disease identifies an additional associated locus. PMID: 21044948
- Saad M et al. (2011). Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. PMID: 21084426
- International Parkinson Disease Genomics Consortium (2011). Imputation of sequence variants for identification of genetic risks for Parkinson's disease. PMID: 21292315
- Do CB et al. (2011). Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PMID: 21738487
Data sources: GWAS Catalog, Open Targets Platform, ClinVar, ClinGen (accessed 2026-05-29).
ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.